In 1882, macrophages were discovered. In 1908, he was awarded the Nobel Prize in Physiology or Medicine for his great contributions to immunological research.

In the late 1980s, Andreesen's team at the University of Regensburg in Germany conducted the first phase I clinical trial of adoptive immunotherapy for cancer patients with MAC generated in vitro by autologous blood mononuclear cells (MO).

In 2008, FN-γ-activated macrophages called MAK cells were used in cancer therapy.

In 2018, researchers at the University of Edinburgh's Centre for Regenerative Medicine conducted the first human clinical trial of autologous macrophages for the treatment of cirrhosis.

2021, RocRock Biology-the global leader in macrophage drugs.

In 2021, Carisma completed the drug administration of the first HER2-targeting CAR-M therapy (CT-0508) in subjects, ushering in a new era of CAR-M modification therapy for solid tumors.

In 2022, the RocRock Bio-AutoCARM project for Solid Tumors was approved for investigator-initiated clinical trials (IIT).